Cabot Wealth Management Inc. Buys 871 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Cabot Wealth Management Inc. increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 5.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,496 shares of the company’s stock after purchasing an additional 871 shares during the period. Cabot Wealth Management Inc. owned 0.05% of Medpace worth $5,480,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of MEDP. Arcadia Investment Management Corp MI acquired a new position in Medpace during the 4th quarter valued at about $72,000. Prakash Investment Advisors LLC bought a new stake in shares of Medpace during the fourth quarter worth approximately $571,000. O Brien Greene & Co. Inc bought a new position in Medpace in the fourth quarter valued at approximately $4,265,000. Ieq Capital LLC grew its holdings in Medpace by 1,090.6% during the 4th quarter. Ieq Capital LLC now owns 27,206 shares of the company’s stock worth $9,039,000 after acquiring an additional 24,921 shares during the period. Finally, Private Advisor Group LLC raised its position in shares of Medpace by 53.8% during the 4th quarter. Private Advisor Group LLC now owns 2,227 shares of the company’s stock valued at $740,000 after acquiring an additional 779 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Price Performance

NASDAQ:MEDP opened at $340.78 on Friday. The business’s 50-day simple moving average is $343.13 and its 200-day simple moving average is $347.20. Medpace Holdings, Inc. has a fifty-two week low of $302.01 and a fifty-two week high of $459.77. The stock has a market capitalization of $10.38 billion, a PE ratio of 26.98, a price-to-earnings-growth ratio of 3.81 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. On average, research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Robert W. Baird raised their price target on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Medpace currently has an average rating of “Hold” and an average price target of $381.44.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.